DIABIL-2Project reference: 305380
Funded under :
Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes
Total cost:EUR 7 603 061,91
EU contribution:EUR 5 900 000
Call for proposal:FP7-HEALTH-2012-INNOVATION-1See other projects for this call
Funding scheme:CP-FP - Small or medium-scale focused research project
The discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.
Low-dose interleukin-2 (ld-IL2) was recently shown to stimulate Tregs without stimulating effector T cells. In NOD mice, ld-IL2 can prevent and cure T1D. In humans, (i) we showed that ld-IL2 is safe, induces Tregs and is associated with clinical improvement in patients with autoimmune vasculitis; and (ii) we performed a dose-finding study in T1D to define an ultra-low dose IL-2 (uld-IL2) that is well tolerated and induces Tregs’ numbers and functionality.
With this strong background – a well defined mechanism of action; proof of concept in NOD mice; proof of principle in a clinical trial with another autoimmune disease; safety and activity/efficacy data in T1D – we propose a phase-II clinical trial testing the efficacy of uld-IL2 for preserving ß-cells.
This will be a double-blind randomised placebo-controlled, age-stratified (6-35 year), multicentre European trial assessing efficacy and safety of uld-IL2 (0.5M IU/m2/day with a maximum of 1 MIU/m2/day for adult patients) in 138 recently-diagnosed T1D patients. Our methodology strictly follows the Immunology of Diabetes Society consensus recommendations and European regulatory guidelines. The primary end-point is the change from baseline of AUC C-peptide during a mixed meal test at 1 year. The trial is precisely and conservatively powered to detect an effect size of d=0.5.
If successful, this trial will have profound impacts for the management of patients with recently-diagnosed T1D, their families and EU economy. It will be a milestone towards preventing T1D in people at risk of this increasingly common childhood disease.
EU contribution: EUR 2 865 483,56
3 Avenue Victoria
Tel.: +33 1 44 84 17 83
Fax: +331 44 84 17 88
EU contribution: EUR 310 193
Rue Watt 7
Tel.: +33 1 55 03 01 43
Fax: +33 1 55 03 01 60
EU contribution: EUR 3 137,96
TRINITY LANE THE OLD SCHOOLS
CB2 1TN CAMBRIDGE
EU contribution: EUR 360 000
Tel.: +41 61 265 50 78
EU contribution: EUR 2 040 211,44
RUE DU FAUBOURG SAINT-ANTOINE 212
Tel.: +33 1 57 27 45 61
EU contribution: EUR 133 637,24
Im Neuenheimer Feld 280
EU contribution: EUR 187 336,8
2333 ZA LEIDEN
Tel.: +31 0715297356